Considerations in the Choice of an Antiepileptic Drug in the Treatment of Epilepsy

ABSTRACT

The advent of multiple new antiepileptic drugs (AEDs) in the past 15 years has provided new options for clinicians treating patients with epilepsy, but has also created a need for guidelines in AED use. For selection of the most appropriate AED, the neurologist must know the pharmacological properties of the AEDs and has to balance their benefits and potential risks for the individual patient. A key consideration in AED selection is spectrum of efficacy for seizure types and epileptic syndrome. Other factors in AED selection include safety and tolerability, ease of use and titration rate, potential interactions, and efficacy in coexisting nonepileptic conditions. Comorbid conditions may favor or exclude the use of certain AEDs in a particular patient. Special considerations apply in specific epilepsy populations, such as women of childbearing age, children, and the elderly. This article analyzes the various factors involved in choosing an AED.

KEYWORDS

Epilepsy - antiepileptic drugs - spectrum of efficacy - tolerability - safety

REFERENCES

• 1 [No authors listed] . Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy.  Epilepsia. 1981;  22 489-501
• 2 French J A, Kanner A M, Bautista J et al.. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.  Neurology. 2004;  62 1252-1260
• 3 Brodie M J, Chadwick D W, Anhut H et al.. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy.  Epilepsia. 2002;  43 993-1000
• 4 Chadwick D W, Anhut H, Greiner M J et al.. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77.  Neurology. 1998;  51 1282-1288
• 5 Brodie M J, Richens A, Yuen A W. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group.  Lancet. 1995;  345 476-479
• 6 Brodie M J, Overstall P W, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group.  Epilepsy Res. 1999;  37 81-87
• 7 Saetre E, Perucca E, Isojarvi J, Gjerstad L. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly.  Epilepsia. 2007;  48 1292-1302
• 8 Rowan A J, Ramsay R E, Collins J F et al.. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine.  Neurology. 2005;  64 1868-1873
• 9 Brodie M J, Perucca E, Ryvlin P, Ben-Menachem E, Meencke H J. Levetiracetam Monotherapy Study Group . Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy.  Neurology. 2007;  68 402-408
• 10 Mattson R H, Cramer J A, Collins J F et al.. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures.  N Engl J Med. 1985;  313 145-151
• 11 Mattson R H, Cramer J A, Collins J F. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group.  N Engl J Med. 1992;  327 765-771
• 12 Isojarvi J I, Laatikainen T J, Pakarinen A J, Juntunen K T, Myllyla V V. Menstrual disorders in women with epilepsy receiving carbamazepine.  Epilepsia. 1995;  36 676-681
• 13 Isojarvi J I, Repo M, Pakarinen A J, Lukkarinen O, Myllyla V V. Carbamazepine, phenytoin, sex hormones, and sexual function in men with epilepsy.  Epilepsia. 1995;  36 366-370
• 14 Rattya J, Turkka J, Pakarinen A J et al.. Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy.  Neurology. 2001;  56 31-36
• 15 Isojarvi J I, Pakarinen A J, Rautio A, Pelkonen O, Myllyla V V. Serum sex hormone levels after replacing carbamazepine with oxcarbazepine.  Eur J Clin Pharmacol. 1995;  47 461-464
• 16 Bill P A, Vigonius U, Pohlmann H et al.. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy.  Epilepsy Res. 1997;  27 195-204
• 17 Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy.  Epilepsy Res. 1989;  3 70-76
• 18 Guerreiro M M, Vigonius U, Pohlmann H et al.. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy.  Epilepsy Res. 1997;  27 205-213
• 19 Babayigit A, Dirik E, Bober E, Cakmakci H. Adverse effects of antiepileptic drugs on bone mineral density.  Pediatr Neurol. 2006;  35 177-181
• 20 Mintzer S, Boppana P, Toguri J, DeSantis A. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine.  Epilepsia. 2006;  47 510-515
• 21 Isojarvi J I, Huuskonen U E, Pakarinen A J, Vuolteenaho O, Myllyla V V. The regulation of serum sodium after replacing carbamazepine with oxcarbazepine.  Epilepsia. 2001;  42 741-745
• 22 Dong X, Leppik I E, White J, Rarick J. Hyponatremia from oxcarbazepine and carbamazepine.  Neurology. 2005;  65 1976-1978
• 23 Marson A G, Al-Kharusi A M, Alwaidh M et al.. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial.  Lancet. 2007;  369 1000-1015
• 24 Gillham R, Kane K, Bryant-Comstock L, Brodie M J. A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure.  Seizure. 2000;  9 375-379
• 25 Meador K J, Loring D W, Ray P G et al.. Differential cognitive and behavioral effects of carbamazepine and lamotrigine.  Neurology. 2001;  56 1177-1182
• 26 Sheth R D, Hermann B P. Bone mineral density with lamotrigine monotherapy for epilepsy.  Pediatr Neurol. 2007;  37 250-254
• 27 Pack A M, Morrell M J, Marcus R et al.. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy.  Ann Neurol. 2005;  57 252-257
• 28 Karceski S, Morrell M J, Carpenter D. Treatment of epilepsy in adults: expert opinion. 2005.  Epilepsy Behav. 2005;  7(suppl 1) S1-S64 , quiz S65–67
• 29 Genton P, Gelisse P, Thomas P, Dravet C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy?.  Neurology. 2000;  55 1106-1109
• 30 Yang M T, Lee W T, Chu L W, Shen Y Z. Anti-epileptic drugs-induced de novo absence seizures.  Brain Dev. 2003;  25 51-56
• 31 Gelisse P, Genton P, Kuate C et al.. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies.  Epilepsia. 2004;  45 1282-1286
• 32 Kaddurah A K, Holmes G L. Possible precipitation of myoclonic seizures with oxcarbazepine.  Epilepsy Behav. 2006;  8 289-293
• 33 Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures.  Epilepsia. 1998;  39 5-17
• 34 Meador K J, Baker G A, Finnell R H et al.. In utero antiepileptic drug exposure: fetal death and malformations.  Neurology. 2006;  67 407-412
• 35 Marson A G, Al-Kharusi A M, Alwaidh M et al.. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.  Lancet. 2007;  369 1016-1026
• 36 Coppola G, Auricchio G, Federico R, Carotenuto M, Pascotto A. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study.  Epilepsia. 2004;  45 1049-1053
• 37 Buoni S, Grosso S, Fois A. Lamotrigine in typical absence epilepsy.  Brain Dev. 1999;  21 303-306
• 38 Frank L M, Enlow T, Holmes G L et al.. Lamictal (lamotrigine) monotherapy for typical absence seizures in children.  Epilepsia. 1999;  40 973-979
• 39 Cavitt J, Privitera M. Levetiracetam induces a rapid and sustained reduction of generalized spike-wave and clinical absence.  Arch Neurol. 2004;  61 1604-1607
• 40 Cross J H. Topiramate monotherapy for childhood absence seizures: an open label pilot study.  Seizure. 2002;  11 406-410
• 41 Wilfong A, Schultz R. Zonisamide for absence seizures.  Epilepsy Res. 2005;  64(1–2) 31-34
• 42 Calleja S, Salas-Puig J, Ribacoba R, Lahoz C H. Evolution of juvenile myoclonic epilepsy treated from the outset with sodium valproate.  Seizure. 2001;  10 424-427
• 43 Obeid T, Panayiotopoulos C P. Clonazepam in juvenile myoclonic epilepsy.  Epilepsia. 1989;  30 603-606
• 44 Andermann E, Andermann F, Meyvisch P, Vandendriessche A, Schiemann Delgado J. Seizure control with levetiracetam in juvenile myoclonic epilepsies.  Epilepsia. 2005;  46(suppl 8) 205
• 45 Krauss G L, Betts T, Abou-Khalil B et al.. Levetiracetam treatment of idiopathic generalised epilepsy.  Seizure. 2003;  12 617-620
• 46 Sharpe D V, Patel A D, Abou-Khalil B, Fenichel G M. Levetiracetam monotherapy in juvenile myoclonic epilepsy.  Seizure. 2008;  17 64-68
• 47 Prasad A, Kuzniecky R I, Knowlton R C et al.. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy.  Arch Neurol. 2003;  60 1100-1105
• 48 Kothare S V, Valencia I, Khurana D S et al.. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy.  Epileptic Disord. 2004;  6 267-270
• 49 Biraben A, Allain H, Scarabin J M, Schuck S, Edan G. Exacerbation of juvenile myoclonic epilepsy with lamotrigine.  Neurology. 2000;  55 1758
• 50 Carrazana E J, Wheeler S D. Exacerbation of juvenile myoclonic epilepsy with lamotrigine.  Neurology. 2001;  56 1424-1425
• 51 Beghi E, Gatti G, Tonini C et al.. Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial.  Epilepsy Res. 2003;  57 1-13
• 52 Kwan P, Brodie M J. Epilepsy after the first drug fails: substitution or add-on?.  Seizure. 2000;  9 464-468
• 53 Albani F, Grassi B, Ferrara R, Turrini R, Baruzzi A. Immediate (overnight) switching from carbamazepine to oxcarbazepine monotherapy is equivalent to a progressive switch.  Seizure. 2004;  13 254-263
• 54 Kwan P, Brodie M J. Early identification of refractory epilepsy.  N Engl J Med. 2000;  342 314-319
• 55 Beydoun A, Fischer J, Labar D R et al.. Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83.  Neurology. 1997;  49 746-752
• 56 Besag F M, Berry D J, Pool F, Newbery J E, Subel B. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?.  Epilepsia. 1998;  39 183-187
• 57 Kwan P, Brodie M J. Combination therapy in epilepsy: when and what to use.  Drugs. 2006;  66 1817-1829
• 58 Brodie M J, Yuen A W. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group.  Epilepsy Res. 1997;  26 423-432
• 59 Kinirons P, McCarthy M, Doherty C P, Delanty N. Predicting drug-resistant patients who respond to add-on therapy with levetiracetam.  Seizure. 2006;  15 387-392
• 60 French J A, Kanner A M, Bautista J et al.. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.  Neurology. 2004;  62 1261-1273
• 61 Marson A G, Kadir Z A, Hutton J L, Chadwick D W. The new antiepileptic drugs: a systematic review of their efficacy and tolerability.  Epilepsia. 1997;  38 859-880
• 62 Peters J M, Camfield C S, Camfield P R. Population study of benign rolandic epilepsy: is treatment needed?.  Neurology. 2001;  57 537-539
• 63 Glauser T, Ben-Menachem E, Bourgeois B et al.. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.  Epilepsia. 2006;  47 1094-1120
• 64 Kang H C, Eun B L, Wu Lee C et al.. The effects on cognitive function and behavioral problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy.  Epilepsia. 2007;  48 1716-1723
• 65 Verrotti A, Coppola G, Manco R et al.. Levetiracetam monotherapy for children and adolescents with benign rolandic seizures.  Seizure. 2007;  16 271-275
• 66 Coppola G, Franzoni E, Verrotti A et al.. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial.  Brain Dev. 2007;  29 281-284
• 67 Tzitiridou M, Panou T, Ramantani G et al.. Oxcarbazepine monotherapy in benign childhood epilepsy with centrotemporal spikes: a clinical and cognitive evaluation.  Epilepsy Behav. 2005;  7 458-467
• 68 Motte J, Trevathan E, Arvidsson J F et al.. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group.  N Engl J Med. 1997;  337 1807-1812
• 69 Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). The Felbamate Study Group in Lennox-Gastaut Syndrome.  N Engl J Med. 1993;  328 29-33
• 70 Sachdeo R C, Glauser T A, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group.  Neurology. 1999;  52 1882-1887
• 71 Biton V, Bourgeois B F. Topiramate in patients with juvenile myoclonic epilepsy.  Arch Neurol. 2005;  62 1705-1708
• 72 Nicolson A, Appleton R E, Chadwick D W, Smith D F. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies.  J Neurol Neurosurg Psychiatry. 2004;  75 75-79
• 73 Pellock J M, Brodie M J. Felbamate: 1997 update.  Epilepsia. 1997;  38 1261-1264
• 74 Dreifuss F E, Santilli N, Langer D H et al.. Valproic acid hepatic fatalities: a retrospective review.  Neurology. 1987;  37 379-385
• 75 White J R, Walczak T S, Leppik I E et al.. Discontinuation of levetiracetam because of behavioral side effects: a case-control study.  Neurology. 2003;  61 1218-1221
• 76 Blum D, Meador K, Biton V et al.. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy.  Neurology. 2006;  67 400-406
• 77 Biton V. Weight change and antiepileptic drugs: health issues and criteria for appropriate selection of an antiepileptic agent.  Neurologist. 2006;  12 163-167
• 78 Bryant III A E, Dreifuss F E. Valproic acid hepatic fatalities: III. US experience since 1986.  Neurology. 1996;  46 465-469
• 79 Nadkarni S, LaJoie J, Devinsky O. Current treatments of epilepsy.  Neurology. 2005;  64(suppl 3) S2-S11
• 80 Lofgren E, Mikkonen K, Tolonen U et al.. Reproductive endocrine function in women with epilepsy: the role of epilepsy type and medication.  Epilepsy Behav. 2007;  10 77-83
• 81 Isojarvi J I, Rattya J, Myllyla V V et al.. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy.  Ann Neurol. 1998;  43 446-451
• 82 Wyszynski D F, Nambisan M, Surve T et al.. Increased rate of major malformations in offspring exposed to valproate during pregnancy.  Neurology. 2005;  64 961-965
• 83 Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study.  Acta Paediatr. 2004;  93 174-176
• 84 Viinikainen K, Eriksson K, Monkkonen A et al.. The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children.  Epilepsy Behav. 2006;  9 636-640
• 85 Vajda F J, Eadie M J. Maternal valproate dosage and foetal malformations.  Acta Neurol Scand. 2005;  112 137-143
• 86 Morrow J, Russell A, Guthrie E et al.. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register.  J Neurol Neurosurg Psychiatry. 2006;  77 193-198
• 87 Artama M, Auvinen A, Raudaskoski T, Isojarvi I, Isojarvi J. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring.  Neurology. 2005;  64 1874-1878
• 88 Montouris G. Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry.  Epilepsy Behav. 2003;  4 310-317
• 89 Hunt S, Craig J, Russell A et al.. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register.  Neurology. 2006;  67 1876-1879
• 90 Hauser W A, Annegers J F, Kurland L T. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984.  Epilepsia. 1993;  34 453-468
• 91 Perucca E, Berlowitz D, Birnbaum A et al.. Pharmacological and clinical aspects of antiepileptic drug use in the elderly.  Epilepsy Res. 2006;  68(S1) S49-S63
• 92 Armon C, Shin C, Miller P et al.. Reversible parkinsonism and cognitive impairment with chronic valproate use.  Neurology. 1996;  47 626-635
• 93 Ferrendelli J A, French J, Leppik I et al.. Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial.  Epilepsy Behav. 2003;  4 702-709
• 94 Groselj J, Guerrini R, Van Oene J et al.. Experience with topiramate monotherapy in elderly patients with recent-onset epilepsy.  Acta Neurol Scand. 2005;  112 144-150